- Home
- CRDF vs LUNG Comparison
CRDF vs LUNG Comparison
Compare CRDF & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- LUNG
- Stock Information
- Founded
- CRDF 1999
- LUNG 1995
- Country
- CRDF United States
- LUNG United States
- Employees
- CRDF N/A
- LUNG N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- LUNG Industrial Specialties
- Sector
- CRDF Health Care
- LUNG Health Care
- Exchange
- CRDF Nasdaq
- LUNG Nasdaq
- Market Cap
- CRDF 210.2M
- LUNG 124.0M
- IPO Year
- CRDF N/A
- LUNG 2020
- Fundamental
- Price
- CRDF $3.66
- LUNG $2.78
- Analyst Decision
- CRDF Strong Buy
- LUNG Buy
- Analyst Count
- CRDF 5
- LUNG 6
- Target Price
- CRDF $10.50
- LUNG $11.53
- AVG Volume (30 Days)
- CRDF 1.5M
- LUNG 311.3K
- Earning Date
- CRDF 08-07-2025
- LUNG 07-30-2025
- Dividend Yield
- CRDF N/A
- LUNG N/A
- EPS Growth
- CRDF N/A
- LUNG N/A
- EPS
- CRDF N/A
- LUNG N/A
- Revenue
- CRDF $587,000.00
- LUNG $87,473,000.00
- Revenue This Year
- CRDF N/A
- LUNG $18.02
- Revenue Next Year
- CRDF N/A
- LUNG $18.17
- P/E Ratio
- CRDF N/A
- LUNG N/A
- Revenue Growth
- CRDF N/A
- LUNG 19.84
- 52 Week Low
- CRDF $2.01
- LUNG $2.50
- 52 Week High
- CRDF $5.64
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- CRDF 58.81
- LUNG 41.83
- Support Level
- CRDF $3.07
- LUNG $2.52
- Resistance Level
- CRDF $3.24
- LUNG $2.84
- Average True Range (ATR)
- CRDF 0.23
- LUNG 0.16
- MACD
- CRDF 0.00
- LUNG 0.04
- Stochastic Oscillator
- CRDF 67.96
- LUNG 46.36
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.